Poor prognosis in triple-negative breast cancers (TNBC; negative for estrogen receptor [ER-], progesterone receptor [PR-], and HER2 receptor [HER2-]) has been frequently associated with TAMs (Wang et al., 2022; Yuan et al., 2014). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.